サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1577510

非インスリン糖尿病治療薬の世界市場

Non-Insulin Diabetes Therapeutics

出版日
ページ情報
英文 192 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
非インスリン糖尿病治療薬の世界市場
出版日: 2024年10月25日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非インスリン糖尿病治療薬の世界市場は2030年までに921億米ドルに到達

2023年に497億米ドルと推定された非インスリン糖尿病治療薬の世界市場は、2023～2030年の分析期間においてCAGR 9.2%で成長し、2030年には921億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるDPP4阻害剤は、CAGR 10.3%を記録し、分析期間終了時には379億米ドルに達すると予測されます。GLP-1受容体作動薬セグメントの成長率は、分析期間のCAGRで9.2%と推定されます。

米国市場は推定135億米ドル、中国はCAGR 12.9%で成長予測

米国の非インスリン糖尿病治療薬市場は2023年に135億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに195億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは12.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.8%と7.9%と予測されています。欧州では、ドイツがCAGR 7.3%で成長すると予測されています。

世界の非インスリン糖尿病治療薬市場- 主要動向と促進要因のまとめ

なぜ非インスリン糖尿病治療薬が注目を集めているのか？

世界のヘルスケアは、糖尿病治療において急速な進化を遂げており、特に非インスリン治療薬に注目が集まっています。このような関心の高まりは、インスリンに代わる治療法の必要性に根ざしたものです。インスリンはその有効性にもかかわらず、定期的な注射の必要性、低血糖のリスク、ライフスタイルの乱れなど、患者にとっていくつかの課題があります。メトホルミン、GLP-1受容体作動薬、SGLT2阻害薬、DPP-4阻害薬などの薬剤を含む非インスリン療法は、2型糖尿病患者にとってより便利で、時には安全な代替療法を提供します。これらの薬剤は、体内のインスリン感受性を高め、グルコースの産生を抑制し、過剰なグルコースの排泄を促進することによって作用します。何百万人もの患者さんにとって、これらの経口薬や注射薬はインスリン注射への依存を減らし、コンプライアンスと全体的な生活の質を向上させる。最近の臨床試験では、ある種の非インスリン療法が血糖値のコントロールに役立つだけでなく、糖尿病患者にとって重大な関心事である心血管リスクを軽減できることも示されています。心血管疾患は糖尿病患者における死亡の主な原因であるため、この2つの利点が非インスリン治療薬の世界の採用増加の主な要因となっています。

さらに、人口の高齢化、都市化、食生活の乱れや運動不足などのライフスタイル要因により、2型糖尿病の世界の有病率は上昇を続けており、ヘルスケアシステムは、より費用対効果が高く、拡張性のある治療オプションを提供する必要に迫られています。非インスリン療法は、インスリン注射よりも侵襲性が低く、投与が容易であるため、新興国市場でも先進国市場でも、説得力のある解決策となります。これらの治療法が支持を集めているもう一つの理由は、患者のQOLの面で長期的なメリットがあることがヘルスケア専門家の間で認識されつつあることです。頻繁な注射とは対照的に、経口錠剤の利便性は患者の治療レジメンへのアドヒアランスを著しく向上させ、これは糖尿病のような慢性疾患の管理には不可欠です。さらに、非インスリン製剤は体重増加のリスクが低いことが多く、これも多くの患者や臨床医に好まれる要因となっています。

この市場を形成する上で、技術革新はどのような役割を果たしているか？

技術革新は、成長する非インスリン糖尿病治療薬市場の核心です。製薬会社は、血糖値を効果的にコントロールするために複数のメカニズムを利用する併用療法の開発にますます力を注いでいます。例えば、SGLT2阻害薬とGLP-1受容体作動薬との併用が増加傾向にあり、これはグルコース調節を両側から狙うものです。この二重作用のアプローチは、グルコースコントロールを改善するだけでなく、体重管理や心血管リスクなど、2型糖尿病の多面的な側面にも対処します。もう一つの重要な技術革新は、投与回数を減らすことができる徐放性薬剤の製剤化であり、これにより患者のコンプライアンスが大幅に改善されます。GLP-1製剤のような週1回投与の注射剤は特に人気があり、患者に病態管理の自由度と柔軟性を提供しています。このような患者中心のイノベーションへの注目は、非インスリン療法の採用を推進する上で重要な役割を果たしています。

さらに現在、研究は従来のメカニズムの枠を超え、糖尿病を標的とする新しい方法を探求しています。そのようなフロンティアのひとつが、消化管内の細菌組成を変化させることで血糖値を調節することを目的とした腸内細菌叢療法の利用です。このような治療法は、まだ大部分が臨床試験中であるが、身体の自然なプロセスを活用することで、非侵襲的かつ長期的な糖尿病管理の可能性を提供するものです。インスリン抵抗性やβ細胞機能不全の根本的な遺伝的原因を修正することで、いつの日か糖尿病の恒久的な解決策を提供できるかもしれないです。これらの技術革新が進展すれば、患者が利用できる治療選択肢の幅が広がるだけでなく、糖尿病の治療法にも革命が起こると期待されています。また、非インスリン療法と連動する持続血糖モニター（CGM）などのデジタルヘルスツールの統合が進むことで、糖尿病管理に対するより密接でデータ主導型のアプローチが生まれ、より個別化された正確な治療計画が可能になります。

消費者の嗜好は非インスリン治療薬市場をどのように牽引するか？

患者の嗜好や行動は、非インスリン糖尿病治療薬市場の成長促進要因として極めて重要です。糖尿病患者の間では、使いやすさと副作用の少なさから非インスリン治療薬が好まれるという顕著な変化が観察されています。世界の糖尿病罹患率の増加は、都市化、座りがちなライフスタイル、肥満率の上昇が大きな要因となっており、よりシンプルで管理しやすい治療レジメンへの需要が高まっています。インスリンを毎日使用するのに比べ、経口投与や注射の頻度が少ないという利便性から、多くの患者が非インスリン療法に惹かれています。さらに、低血糖のリスクが低いことは、インスリン治療の潜在的に危険な副作用であり、非インスリン治療薬は特に魅力的です。何百万人もの患者にとって糖尿病管理が日常生活の一部となるにつれ、患者は柔軟性があり、食事や活動の制限が少なく、より低コストの治療法を求めています。このような、より便利でライフスタイルに合った治療を求める消費者の要望は、非インスリン治療薬の開発と採用を促進する強力な力となっています。

さらに、デジタルヘルスプラットフォームや遠隔医療を通じて最新の治療選択肢に関する情報を容易に入手できるため、ヘルスケアに関する意思決定に関与する患者が増加しています。このようなエンパワーメントは、患者が自分の選択についてより多くの情報を得、ライフスタイルの嗜好に沿った治療を優先するようになり、非インスリン治療へのシフトをさらに促しています。消費者行動に影響を与えるもう一つの重要な要因は、予防ヘルスケアへの傾向の高まりであり、インスリンの必要性が生じる前に血糖値を管理するための早期介入を選択する個人が増加しています。特に2型糖尿病の初期段階にある新規診断患者には、第一選択治療としてインスリン以外の治療薬が処方されることが多いです。この動向は、最新の医療技術を求め、利便性と長期的な健康成果を優先する傾向が強い、技術に精通した若い患者に特に顕著です。全体として、消費者の嗜好は、効果的であるだけでなく、使い勝手がよく、現代のライフスタイルの要求に沿った治療を求めることによって、非インスリン糖尿病治療薬市場の形成に重要な役割を果たしています。

非インスリン治療薬市場の成長の原動力は？

非インスリン糖尿病治療薬市場の成長は、技術の進歩、糖尿病人口の増加、ヘルスケア政策の進化など、いくつかの要因によって牽引されています。非インスリン治療薬と連動する徐放性製剤、配合剤、持続グルコース監視装置などの技術革新は、市場拡大において極めて重要な役割を果たしています。これらの進歩により、非インスリン治療の有効性と利便性が向上し、患者とヘルスケア提供者の双方にとってより魅力的なものとなっています。さらに、特に都市化とライフスタイルの変化により肥満率が急上昇している新興経済圏における2型糖尿病患者の増加が、これらの治療法の対応可能市場を大幅に拡大しています。アジア太平洋やラテンアメリカなど、ヘルスケアのインフラが整備され、最新の治療法へのアクセスが拡大している地域では、非インスリン糖尿病治療薬が台頭しつつあります。さらに、世界人口の高齢化に伴い、糖尿病の有病率は上昇を続けており、患者の日常生活に簡単に取り入れることができる効果的で利用しやすい治療法に対する需要がさらに高まっています。

さらに、進化するヘルスケア政策が市場の牽引役として重要な役割を果たしています。多くの政府やヘルスケア機関は、糖尿病流行の管理を目的とした広範な公衆衛生キャンペーンの一環として、インスリン以外の治療法の使用を積極的に推進しています。例えば、早期診断と予防医療を奨励する政策により、新規診断患者の第一選択薬として非インスリン製剤の使用が増加しています。さらに、治療が有効性だけでなく長期的な費用対効果も含めて評価されるバリューベースのヘルスケアモデルが重視されるようになり、インスリンベースの治療と比較して費用対効果が高いとされる非インスリン製剤の採用が加速しています。さらに、多くの保険会社が非インスリン製剤の保険適用を拡大しており、より幅広い患者が非インスリン製剤を利用しやすくなっています。このような技術革新、人口動態の変化、支持的な政策枠組みの組み合わせが、世界規模での市場セグメンテーション市場の成長を後押ししており、医薬品業界の中でも最もダイナミックで変化の速い分野の一つとなっています。

調査対象企業の例（全48件）

  • 3SBio, Inc.
  • Abbott Laboratories, Inc.
  • Alkem Laboratories Limited
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Gemopharm LLC
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP24315

Global Non-Insulin Diabetes Therapeutics Market to Reach US$92.1 Billion by 2030

The global market for Non-Insulin Diabetes Therapeutics estimated at US$49.7 Billion in the year 2023, is expected to reach US$92.1 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2023-2030. DPP4 Inhibitors, one of the segments analyzed in the report, is expected to record a 10.3% CAGR and reach US$37.9 Billion by the end of the analysis period. Growth in the GLP-1 Receptor Agonists segment is estimated at 9.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$13.5 Billion While China is Forecast to Grow at 12.9% CAGR

The Non-Insulin Diabetes Therapeutics market in the U.S. is estimated at US$13.5 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$19.5 Billion by the year 2030 trailing a CAGR of 12.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.8% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.3% CAGR.

Global Non-Insulin Diabetes Therapeutics Market - Key Trends & Drivers Summarized

Why Are Non-Insulin Diabetes Therapeutics Gaining Traction?

The global healthcare landscape is witnessing a rapid evolution in the treatment of diabetes, with a particular focus on non-insulin therapeutics. This surge in interest is rooted in the need for alternative treatments to insulin, which, despite its efficacy, presents several challenges for patients such as the need for regular injections, risk of hypoglycemia, and lifestyle disruptions. Non-insulin therapies, which include drugs like metformin, GLP-1 receptor agonists, SGLT2 inhibitors, and DPP-4 inhibitors, offer a more convenient and sometimes safer alternative for Type 2 diabetes patients. These drugs work by enhancing the body’s insulin sensitivity, reducing glucose production, and promoting the excretion of excess glucose. For millions of patients, these oral or injectable medications reduce the reliance on insulin injections, thus improving compliance and overall quality of life. Recent clinical trials have also shown that certain non-insulin therapies not only help control blood glucose levels but can also reduce cardiovascular risks, a significant concern for diabetic patients. As cardiovascular diseases are the leading cause of mortality in diabetic patients, this dual benefit has been a major factor in the increasing adoption of non-insulin therapeutics globally.

Furthermore, as the global prevalence of Type 2 diabetes continues to rise due to aging populations, urbanization, and lifestyle factors such as poor diet and lack of exercise, healthcare systems are under pressure to provide more cost-effective and scalable treatment options. Non-insulin therapies, being less invasive and more easily administered than insulin injections, represent a compelling solution in both developing and developed markets. Another reason these therapies are gaining traction is the growing recognition among healthcare professionals of the long-term benefits they offer in terms of patient quality of life. The convenience of oral tablets, as opposed to frequent injections, significantly improves patient adherence to treatment regimens, which is critical for the management of a chronic condition like diabetes. Moreover, non-insulin drugs often come with a lower risk of weight gain, another factor that has made them a preferred option for many patients and clinicians alike.

What Role Does Innovation Play In Shaping This Market?

Technological innovation is at the heart of the growing non-insulin diabetes therapeutics market. Pharmaceutical companies are increasingly focusing on the development of combination therapies that utilize multiple mechanisms to control blood sugar levels effectively. For example, a growing trend is the use of SGLT2 inhibitors in combination with GLP-1 receptor agonists, which targets glucose regulation from both ends—preventing glucose reabsorption by the kidneys while stimulating insulin production in the pancreas. This dual-action approach not only helps in better glucose control but also addresses multiple facets of Type 2 diabetes, such as weight management and cardiovascular risk. Another significant area of innovation is the formulation of extended-release medications that allow for less frequent dosing, which greatly improves patient compliance. Once-weekly injectables, like those in the GLP-1 class, have been particularly popular, offering patients more freedom and flexibility in managing their condition. This focus on patient-centric innovations has played a crucial role in driving the adoption of non-insulin therapies.

Furthermore, research is now pushing the boundaries beyond traditional mechanisms, exploring novel ways to target diabetes. One such frontier is the use of gut microbiome therapies, which aim to regulate blood glucose levels by altering the bacterial composition in the digestive tract. These therapies, still largely in clinical trials, offer the potential for non-invasive, long-term management of diabetes by leveraging the body's natural processes. Another exciting development is the exploration of gene-editing technologies, such as CRISPR, which could one day provide a permanent solution for diabetes by correcting the underlying genetic causes of insulin resistance or beta-cell dysfunction. As these innovations progress, they are expected to not only expand the range of therapeutic options available to patients but also revolutionize the way diabetes is treated. The ongoing integration of digital health tools, such as continuous glucose monitors (CGMs) that work in tandem with non-insulin therapies, is also creating a more connected, data-driven approach to diabetes management, enabling more personalized and precise treatment plans.

How Do Consumer Preferences Drive The Non-Insulin Therapeutics Market?

Patient preferences and behaviors are crucial drivers of growth in the non-insulin diabetes therapeutics market. A noticeable shift has been observed among diabetes patients, with many favoring non-insulin medications due to their ease of use and fewer associated side effects. The global increase in diabetes prevalence, largely fueled by urbanization, sedentary lifestyles, and rising obesity rates, has heightened the demand for simpler, more manageable treatment regimens. Many patients are drawn to non-insulin therapies because of the convenience of oral administration or less frequent injections compared to daily insulin use. Additionally, the lower risk of hypoglycemia—a potentially dangerous side effect of insulin therapy—makes non-insulin drugs particularly appealing. As diabetes management increasingly becomes a part of routine daily life for millions, patients are seeking therapies that offer flexibility, fewer restrictions on diet and activity, and lower costs. This consumer demand for more convenient, lifestyle-friendly treatments is a powerful force driving the development and adoption of non-insulin therapeutics.

Moreover, an increasing number of patients are becoming more engaged in their healthcare decisions, with access to information about the latest treatment options readily available through digital health platforms and telemedicine. This empowerment is further encouraging the shift toward non-insulin therapies, as patients become more informed about their choices and prioritize treatments that align with their lifestyle preferences. Another significant factor influencing consumer behavior is the growing trend toward preventive healthcare, with more individuals opting for early interventions to manage their blood sugar levels before the need for insulin arises. Non-insulin therapies are often prescribed as first-line treatments for newly diagnosed patients, especially those who are in the early stages of Type 2 diabetes. This trend is particularly prevalent in younger, tech-savvy patients who are more inclined to seek out the latest advancements in medicine and prioritize convenience and long-term health outcomes. Overall, consumer preferences are playing a critical role in shaping the non-insulin diabetes therapeutics market by pushing for treatments that are not only effective but also user-friendly and aligned with modern lifestyle demands.

What Is Driving The Growth Of The Non-Insulin Therapeutics Market?

The growth in the non-insulin diabetes therapeutics market is driven by several factors, including technological advancements, a growing diabetic population, and evolving healthcare policies. Technological innovations such as extended-release formulations, combination drugs, and continuous glucose monitoring devices that work in tandem with non-insulin therapies are playing a pivotal role in market expansion. These advancements have improved the efficacy and convenience of non-insulin treatments, making them more attractive to both patients and healthcare providers. Additionally, the rise in Type 2 diabetes cases, especially in emerging economies where urbanization and lifestyle changes have led to a surge in obesity rates, has significantly expanded the addressable market for these therapies. In regions such as Asia-Pacific and Latin America, where healthcare infrastructure is improving and access to modern treatments is growing, non-insulin diabetes therapies are gaining ground. Moreover, as the global population ages, the prevalence of diabetes continues to rise, further driving demand for effective and accessible treatments that can be easily integrated into patients' daily routines.

Furthermore, evolving healthcare policies are playing a crucial role in driving the market. Many governments and healthcare organizations are actively promoting the use of non-insulin therapies as part of broader public health campaigns aimed at managing the diabetes epidemic. For instance, policies that encourage early diagnosis and preventive care are leading to the increased use of non-insulin medications as first-line therapies for newly diagnosed patients. In addition, the growing emphasis on value-based healthcare models, where treatments are evaluated not just on their efficacy but also on their long-term cost-effectiveness, is boosting the adoption of non-insulin drugs, which are often seen as more cost-efficient compared to insulin-based therapies. Moreover, many insurance companies are expanding coverage for non-insulin medications, making them more accessible to a wider range of patients. This combination of technological innovation, demographic shifts, and supportive policy frameworks is propelling the growth of the non-insulin diabetes therapeutics market on a global scale, making it one of the most dynamic and fast-evolving segments in the pharmaceutical industry.

Select Competitors (Total 48 Featured) -

  • 3SBio, Inc.
  • Abbott Laboratories, Inc.
  • Alkem Laboratories Limited
  • AstraZeneca Plc
  • Boehringer Ingelheim International GmbH
  • Eli Lilly and Company
  • Gemopharm LLC
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Non-Insulin Diabetes Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Prevalence of Diabetes Drives Demand for Non-Insulin Therapeutics
    • Advances in GLP-1 Receptor Agonists Bodes Well for Non-Insulin Therapeutics Market
    • Rising Demand for SGLT2 Inhibitors Drives Adoption of Non-Insulin Therapeutics
    • Growing Focus on Weight Management in Diabetes Care Spurs Market Expansion
    • Increasing Adoption of Non-Pharmacological Interventions Expands Treatment Options
    • Awareness of Long-Term Complications of Insulin Fuels Growth in Non-Insulin Solutions
    • Development of Next-Generation Anti-Diabetic Drugs Strengthens Business Case for Growth
    • Expanding Geriatric Population Accelerates Demand for Non-Insulin Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Non-Insulin Diabetes Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for DPP4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for DPP4 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for DPP4 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for GLP-1 Receptor Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for GLP-1 Receptor Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for SGLT2 Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for SGLT2 Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 17: USA Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 18: USA Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: USA 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 21: Canada Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: Canada 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • JAPAN
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 23: Japan Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: Japan Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: Japan 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • CHINA
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: China Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: China 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • EUROPE
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 29: Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 30: Europe Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Europe Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • FRANCE
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 35: France Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: France Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: France 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • GERMANY
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 38: Germany Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Germany Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Germany 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 41: Italy Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Italy Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Italy 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 44: UK Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: UK Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: UK 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • SPAIN
    • TABLE 47: Spain Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Spain Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Spain 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • RUSSIA
    • TABLE 50: Russia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Russia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: Russia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 53: Rest of Europe Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: Rest of Europe Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: Rest of Europe 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 56: Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 57: Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
    • TABLE 59: Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • AUSTRALIA
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
    • TABLE 62: Australia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Australia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Australia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • INDIA
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
    • TABLE 65: India Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: India Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: India 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • SOUTH KOREA
    • TABLE 68: South Korea Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: South Korea Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: South Korea 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 71: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Rest of Asia-Pacific Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Rest of Asia-Pacific 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • LATIN AMERICA
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
    • TABLE 74: Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 75: Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
    • TABLE 77: Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • ARGENTINA
    • TABLE 80: Argentina Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Argentina Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Argentina 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • BRAZIL
    • TABLE 83: Brazil Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Brazil Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Brazil 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • MEXICO
    • TABLE 86: Mexico Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Mexico Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Mexico 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • REST OF LATIN AMERICA
    • TABLE 89: Rest of Latin America Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Rest of Latin America Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Rest of Latin America 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • MIDDLE EAST
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
    • TABLE 92: Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 93: Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
    • TABLE 95: Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • IRAN
    • TABLE 98: Iran Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: Iran Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: Iran 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • ISRAEL
    • TABLE 101: Israel Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: Israel Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: Israel 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • SAUDI ARABIA
    • TABLE 104: Saudi Arabia Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: Saudi Arabia Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: Saudi Arabia 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 107: UAE Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: UAE Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: UAE 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • REST OF MIDDLE EAST
    • TABLE 110: Rest of Middle East Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Middle East Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Middle East 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030
  • AFRICA
    • Non-Insulin Diabetes Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
    • TABLE 113: Africa Recent Past, Current & Future Analysis for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Africa Historic Review for Non-Insulin Diabetes Therapeutics by Type - DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Africa 16-Year Perspective for Non-Insulin Diabetes Therapeutics by Type - Percentage Breakdown of Value Sales for DPP4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors and Other Types for the Years 2014, 2024 & 2030

IV. COMPETITION